Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
27.8M
-
Shares change
-
+23.8M
-
Total reported value, excl. options
-
$356M
-
Value change
-
+$311M
-
Put/Call ratio
-
0.27
-
Number of buys
-
46
-
Number of sells
-
-13
-
Price
-
$13.00
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q2 2020
79 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q2 2020.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.8M shares
of 67.8M outstanding shares and own 40.98% of the company stock.
Largest 10 shareholders include BVF INC/IL (2.74M shares), RTW INVESTMENTS, LP (2.61M shares), Redmile Group, LLC (2M shares), Logos Global Management LP (2M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.75M shares), Ikarian Capital, LLC (1.65M shares), RENAISSANCE TECHNOLOGIES LLC (1.64M shares), Vivo Capital, LLC (1.6M shares), VANGUARD GROUP INC (1.3M shares), and RA CAPITAL MANAGEMENT, L.P. (1.15M shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.